Preveceutical - PRVCF STOCK NEWS

PreveCeutical Medical has provided an update on the Management Cease Trade Order (MCTO) issued by the British Columbia Securities Commission due to the company's delay in filing its annual financial statements for the year ended December 31, 2023. The delay was caused by a lack of funds to engage auditors. The company has now engaged Smythe LLP and expects to file the required documents by June 28, 2024. During this period, the CEO, CFO, and certain other officers cannot trade in the company's shares. The general public can continue to trade them. PreveCeutical also plans a private placement to raise up to $250,000 for working capital, including audit fees.

PreveCeutical Medical Inc. announces a Management Cease Trade Order due to missing the deadline for filing annual financial statements. The Company applied for a MCTO as a result of a lack of funds preventing completion of the audit on time. PreveCeutical expects to file the Annual Filings by June 28, 2024, and will provide bi-weekly default status reports until then. Additionally, the Company plans a private placement to raise $250,000 for working capital purposes.

PreveCeutical Medical Inc. (PREV) has started preparations to accelerate completion of its preclinical dual gene therapy program using its developed Smart-siRNA sequences and proprietary bioresponsive lipid-nanoparticulate delivery systems. The company has received interest from a world-leading pharmaceutical company for its diabetes & obesity dual gene therapy program and is seeking funding to complete preclinical studies, with plans to commence in early 2024. CEO Stephen Van Deventer expressed excitement over the validation of their research program and the global need for diabetes and obesity therapeutics.

Endosane Pharmaceuticals will conduct preclinical studies to evaluate the brain delivery characteristics of sol-gel technology and CBD. The study aims to assess the amounts achieved, regional distribution, and time course of CBD uptake in the brain. The research proposal includes experiments on rats to demonstrate the pharmacological relevance of brain CBD concentrations. Collaborative efforts with the University of Sydney have identified anandamide as a potential blood surrogate marker for CBD's brain activity. PreveCeutical and Endosane's dedication to research in CBD delivery and pharmacology shows their commitment to advancing medical knowledge. No concrete business takes affecting stock price are mentioned.

PreveCeutical showcases dynamic evolution in AI strategy

PreveCeutical Medical Inc. has entered into a Service Agreement with New to the Street Group LLC for production and broadcasting services involving television, production, media analysis, and procurement. The agreement includes a total compensation of $150,000, with the first payment of $5,000 due by September 15, 2023, and the remaining five payments of $5,000 due on the 1st of each consecutive month. The term of the agreement is from September 1, 2023, to February 29, 2024.